In Phase C, contributors will receive ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment till ailment progression or perhaps the individuals are not able to tolerate the study drugs. There might be bigger treatment stress for individuals With this trial compared https://abbv-744-in-acute-myeloid02457.dailyhitblog.com/37427477/getting-my-abbv-744-brd4-inhibitor-clinical-efficacy-in-refractory-cancers-to-work